CLINICAL24: Innovations in sepsis and infectious disease diagnostics
13 Nov 2024
Christian Borjesson, President of Microbiology at Beckman Coulter Diagnostics, shares insights on the future of microbiology and infectious disease diagnostics with SelectScience Managing Editor, Sonia Nicholas. Borjesson discusses the evolution of antimicrobial susceptibility testing, the impact of COVID-19 on diagnostic innovations, and the ongoing challenges of managing sepsis. Borjesson highlights emerging technologies like next-generation sequencing and rapid antimicrobial susceptibility testing (AST), which promise faster, more personalized treatments for sepsis and other infections. Borjesson also underscores the need for a coordinated global response to future pandemics and the increasing threat of antimicrobial resistance.
This interview was recorded for CLINICAL24 2024
References:
Timestamp [2:42]: Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. Naghavi, Mohsen et al. The Lancet, Volume 404, Issue 10459, 1199 - 1226
About the company
Beckman Coulter Diagnostics
Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits, service and operating-type lease payments, represents approximately 78 percent of the company s 2007 annual revenue of $2.76 billion. For more information, visit www.beckmancoulter.com.
